Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR plus ) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials.

被引：0
|
作者：
Pagani, Olivia
Regan, Meredith M.
Walley, Barbara
Fleming, Gini F.
Colleoni, Marco
Lang, Istvan
Gomez, Henry Leonidas
Tondini, Carlo
Burstein, Harold J.
Perez, Edith A.
Ciruelos, Eva
Stearns, Vered
Bonnefoi, Herve R.
Martino, Silvana
Geyer, Charles E.
Rabaglio-Poretti, Manuela
Coates, Alan S.
Gelber, Richard D.
Goldhirsch, Aron
Francis, Prudence A.
机构：
[1] SAKK, Inst Oncol Southern Switzerland, Lugano Viganello, Switzerland
[2] IBCSG, Lugano Viganello, Switzerland
[3] Dana Farber Canc Inst, IBCSG Stat Ctr, Boston, MA 02115 USA
[4] NCIC Clin Trials Grp, Kingston, ON, Canada
[5] Univ Chicago, Med Ctr & Alliance, Chicago, IL 60637 USA
[6] European Inst Oncol, Milan, Italy
[7] IBCSG, Milan, Italy
[8] Natl Inst Oncol, Budapest, Hungary
[9] Inst Natl Enfermedades Neoplas, Lima, Peru
[10] IBCSG, Lima, Peru
[11] Osp Papa Giovanni XXIII, Bergamo, Italy
[12] Dana Farber Canc Inst & Alliance, Boston, MA USA
[13] Mayo Clin & Alliance, Jacksonville, FL USA
[14] Univ Hosp 12 Octubre, Madrid, Spain
[15] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[16] ECOG, Baltimore, MD USA
[17] Bergonie Inst, Bordeaux, France
[18] EORTC, Bordeaux, France
[19] Angeles Clin & Res Inst, Santa Monica, CA USA
[20] SWOG, Santa Monica, CA USA
[21] Virginia Commonwealth Univ, Massey Canc Ctr, Sch Med, Richmond, VA USA
[22] NRG Oncol, Richmond, VA USA
[23] Inst Med Oncol, Bern, Switzerland
[24] Int Breast Canc Study Grp, Bern, Switzerland
[25] ANZBCTG, Peter MacCallurn Canc Ctr, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA1
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR plus ) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6)
    Rossi, G.
    Brain, E.
    Dueck, A.
    De Swert, H.
    Marreaud, S. I.
    Partridge, A.
    Herold, C.
    Vachon, H.
    Spanic, T.
    Arahmani, A.
    Verbiest, T.
    Wang, L.
    Goulioti, T.
    Malanda, B.
    Carey, L. A.
    Anneheim, S.
    Paux, G.
    Poncet, C.
    Metzger, O.
    Cameron, D.
    ANNALS OF ONCOLOGY, 2022, 33 : S162 - S163
  • [32] Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials
    Bradley, R.
    Braybrooke, J.
    Gray, R.
    Hills, R. K.
    Liu, Z.
    Pan, H.
    Peto, R.
    Dodwell, D.
    McGale, P.
    Taylor, C.
    Bergh, J.
    Swain, S.
    Francis, P. A.
    Gnant, M.
    Perrone, F.
    Regan, M. M.
    LANCET ONCOLOGY, 2022, 23 (03): : 382 - 392
  • [33] rospective Study of Aromatase Inhibitor Induced Bone Loss and Lipid Levels in Early Postmenopausal (PM) Hormone Receptor Positive (HR plus ) Breast Cancer (BC) Patients Treated with Adjuvant Letrozole Extended beyond 5 Years (yrs).
    Fontaine, C.
    Hanssens, S.
    Van Den Berge, D.
    Decoster, L.
    Schallier, D.
    Declippeleir, D.
    Vanhoeij, M.
    Lamote, J.
    Sacre, R.
    De Greve, J.
    CANCER RESEARCH, 2011, 71
  • [34] Final analysis of a randomized comparison of letrozole (Let) vs observation (Obs) as late reintroduction of adjuvant endocrine therapy (AET) for postmenopausal women with hormone receptor positive (HR plus ) breast cancer (BC) after completion of prior AET: ANZBCTG 0501 (LATER).
    Zdenkowski, Nicholas
    Green, Michael
    Boyle, Frances M.
    Kannourakis, George
    Gill, Peter Grantley
    Bayliss, Evan
    Saunders, Christobel
    Della-Fiorentina, Stephen
    Kling, Neill
    Campbell, Ian
    Gebski, Val
    Veillard, Anne-Sophie
    Davies, Lucy Claire
    Thornton, Rochelle
    Fong, Akiko
    Reaby, Linda Louise
    Forbes, John F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [35] Exploratory subset analysis according to prior endocrine treatment of two randomized phase II trials comparing gefitinib (G) with placebo (P) in combination with tamoxifen (T) or anastrozole (A) in hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Cristofanilli, M.
    Schiff, R.
    Valero, V.
    Iacona, R.
    Yu, J.
    Speake, G.
    Smith, I.
    Osborne, C. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)
    Andre, F.
    Kaufman, B.
    Juric, D.
    Ciruelos, E.
    Iwata, H.
    Mayer, I. A.
    Conte, P.
    Rugo, H. S.
    Loibl, S.
    Rubovszky, G.
    Tesch, H.
    Inoue, K.
    Lu, Y-S.
    Ryvo, L.
    Longin, A-S.
    Mills, D.
    Wilke, C.
    Germa, C.
    Campone, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [37] SOLAR-1: A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy
    Andre, F.
    Kaufman, B.
    Juric, D.
    Ciruelos, E. M.
    Iwata, H.
    Mayer, I. A.
    Rugo, H. S.
    Conte, P.
    Liobl, S.
    Rubovszky, G.
    Inoue, K.
    Tesch, H.
    Lu, Y-S
    Ryvo, L.
    Longin, A-S
    Mills, D.
    Wilke, C.
    Germa, C.
    Campone, M.
    CANCER RESEARCH, 2017, 77
  • [38] Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who received prior chemotherapy (CT): MONALEESA-7 subgroup analysis
    Hurvitz, Sara A.
    Wheatley-Price, Paul
    Tripathy, Debu
    Lu, Yen-Shen
    Chow, Louis
    Bachelot, Thomas Denis
    Hegg, Roberto
    Chia, Stephen K. L.
    Yardley, Denise A.
    Kong, Oliver
    Alam, Jahangir
    Diaz-Padilla, Ivan
    Baeck, Johan
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] Results of ENCORE 301, a randomized, phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive (ER plus ) breast cancer progressing on a nonsteroidal aromatase inhibitor (AI).
    Yardley, D. A.
    Ismail-Khan, R.
    Klein, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [40] A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG 479 With Exemestane (E) or Fulvestrant (F) in Postmenopausal Women With Hormone-Receptor Positive (HR plus ) Metastatic (M) or Locally Advanced (LA) Breast Cancer (BC)
    Kaufman, P. A.
    Ferrero, J. M.
    Bourgeois, H.
    Kennecke, H.
    De Boer, R.
    Jacot, W.
    McGreivy, J.
    Suzuki, S.
    Loh, E.
    Robertson, J.
    CANCER RESEARCH, 2010, 70
12345